Intraperitoneal Administration of Fosfomycin, Metronidazole and Molgramostim Versus Intravenous Antibiotics for Perforated Appendicitis

Appendicitis Perforated Clinical Trial

Official title:
Intraperitoneal Administration of Fosfomycin, Metronidazole and Molgramostim Versus Intravenous Conventional Antibiotics for Perforated Appendicitis - a Pivotal Quasi-randomized Controlled Trial

Status Completed

Clinical Trial Summary

The objective of this trial is to evaluate if intraoperative intraperitoneal administration of fosfomycin, metronidazole and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) followed by oral antibiotic for three days is as effective as the current intravenous antibiotic treatment given during and three days after appendectomy for perforated appendicitis. The primary outcome is the total length of hospital stay, defined as the number of hours in hospital after end of operation and until 30-day follow-up.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03435900
Study type	Interventional
Source	Herlev Hospital
Contact
Status	Completed
Phase	Phase 2
Start date	February 14, 2018
Completion date	July 17, 2018

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06059365` - Clinical Trial for a Outpatient Clinical Management for Complicated Acute Appendicitis	N/A
Recruiting	`NCT04947748` - Short Post-operative Antibacterial Therapy in Complicated Appendicitis: Oral Versus Intravenous	N/A
Not yet recruiting	`NCT05943223` - Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA)	Phase 2
Recruiting	`NCT04755179` - Identification of the Optimal Treatment Strategy for Complex Appendicitis in the Pediatric Population